Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00851955 · ClinicalTrials.gov registry record
Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 150
- Enrollment target
NCT00851955: Completed study, sponsored by Mayo Clinic.
NCT00851955 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00851955 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-11 |
What the finished NCT00851955 record still lists
NCT00851955 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00851955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00851955 about?
NCT00851955 is a clinical study titled "Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer". The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotyp...
What is the current status of trial NCT00851955?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2007-05. Estimated completion is 2011-11.
Who is sponsoring clinical trial NCT00851955?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia